Stockreport

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Palisade Bio, Inc.  (PALI) 
PDF – Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year e [Read more]